Targeted agents for adjuvant therapy of colon cancer

Clinical Colorectal Cancer

Volumn 6, Issue 1, 2006, Pages 46-51

  Wasif Saif, Muhammad ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; Bevacizumab; Capecitabine; Cetuximab; Irinotecan; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BRAIN ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON SURGERY; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; ENTERITIS; FEBRILE NEUTROPENIA; HEART INFARCTION; HUMAN; HYPERTENSION; IMMUNOGENICITY; LOW DRUG DOSE; NEUROTOXICITY; NEUTROPENIA; PROTEIN EXPRESSION; PROTEINURIA; RECURRENCE RISK; REVIEW; SENSORY NEUROPATHY; THROMBOSIS; TREATMENT FAILURE;

EID: 33745904978     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.020     Document Type: Review

References (33)

1. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40:15-24.
2. American Joint Committee on Cancer. Cancer Staging Manual. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1998.
3. Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Center Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7:1447-1456.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-326.
5. Piedbois P, Buyse M, Rustum Y, et al. (Adjuvant colorectal cancer meta-analysis project). Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
6. O'Connell MJ, Maillard JA, Kahn MJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15:246-250.
7. IMPACT. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345:939-944.
8. Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106:899-906.
9. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11:1879-1887.
10. Haller DG, Catalano PJ, Macdonald JS, et al. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc Am Soc Clin Oncol 1998; 17:256a (Abstract #256).
11. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553-3559.
12. de Gramont A, Figer M, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938-2947.
13. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
14. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-2351.
15. Wolmark M, Wieand HS, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP protocol C-07. J Clin Oncol 2005; 23 (16 suppl):246s (Abstract #LBA3500).
16. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
17. Giantonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23(16 suppl): 1s (Abstract #2).
18. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in ininotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
19. Badarinath SM, Mitchell EP, Jennis A, et al. Cetuximab plus FOLFOX for colorectal (EXPLORE): preliminary safety analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23:253 (Abstract #3531).
20. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab + FOLFIRI as first-line treatment for metastatic colorectal cancer. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3513).
21. Lee JC, Chow NH, Wang ST et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000; 36:748-753.
22. Kumar H, Heer K, Lee PW, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4:1279-1285.
23. Chin KF, Greenman J, Gardiner E, et al. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000; 83:1425-1431.
24. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004; 9(suppl 1):36-42.
25. Kim K, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7:53-64.
26. Choi HJ, Hyun MS, Jung GJ, et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 1998; 55:575-581.
27. Fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab in treating patients who have undergone surgery fo stage II or stage III colon cancer. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00096278. Accessed January 19, 2006.
28. Combination chemoherapy with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00079274. Accessed January 19, 2006.
29. Oxaliplatin, leucovorin, and fluorouacil with or without bevacizumab in treating patients who have undergone surgery for stage II and stage III colon cancer. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00217737. Accessed January 19, 2006.
30. Real FX, Rettig WJ, Chesa PG, et al. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46:4726-4731.
31. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7:2958-2970.
32. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30:255-268.
33. Comparison of combination chemotherapy regimens with or without cetuximab in treating patients who have undergone surgery for stage III colon cancer. Available at: http://www.clinicaltrials.gov/ct/gui/show/NCT00079727. Accessed January 19, 2006.